Heald’s money-back guarantee boldly links business success to patient outcomes,” said Dr. Neal Patel, CIO at Vanderbilt ...

Investors may submit written questions in advance of the conference call to [email protected] or through the webcast portal. A replay of the webcast will be available on the Company’s website at ...

RxSight’s management is scheduled to present on Thursday, September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live and archived webcast of the presentation will be available at: ...

The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional ...

Second quarter 2025 revenue was $3.3 million, a 17% increase over the second quarter of 2024. New accounts grew 75% in the second quarter of 2025 over the comparable quarter in 2024. CapsoCam Plus® ...

GTB-3650 TriKE ®  Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2’s formal safety review, it has advanced into Cohort 3 and ...

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study ; Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid- ...

TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three ...

Ended the quarter with $4.8 million in cash following the closing of a private placement pursuant to a securities purchase agreement with an accredited investor for aggregate gross proceeds of $4.25 ...

BioStem Technologies, Inc. (“BioStem” or the “Company”) (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for ...

Fortress’ consolidated net revenue totaled $16.4 million for the second quarter ended June 30, 2025, $15.0 million of which was generated from our marketed dermatology products. This compares to ...

Second Quarter 2025 Financial Results Cash, cash equivalents, and marketable securities as of June 30, 2025, were $39.1 million, compared to $49.3 million as of March 31, 2025.